The draft would loosen limits on how certain peptides can be made in the US. CNN walks through what changes for people seeking them.
Recap by typeshit. Full story at CNN on MSN.
Experts debate how regulators should separate real patient customization from mass-produced copies, citing recent tirzepatide sterility recalls and impurity findings.
A legal walkthrough of the 503A rules behind the October 28 policy, the July advisory vote, and the HHS note that it may revisit the policy if safety signals appear.
The recall came after an FDA warning letter. The Regulatory Review uses it to dig into how compounded GLP-1s stayed on sale after shortages officially ended.
The peptide item sits among gene therapy, Neuralink and Medicare news. The Alliance for Safe Biologic Medicines has asked HHS to pause the policy, citing FDA scientists.
The endocrinologist explains that microdosing means taking far less than the doses recommended for treatment, and gives his view on the trend.
A link to the FDA's list of bulk drug substances it says may carry significant safety risks in compounding, relevant to the peptide policy fight.
Loading…